Chemical & Pharmaceutical Bulletin 2004-08-01

N-phenylphthalimide-type cyclooxygenase (COX) inhibitors derived from thalidomide: substituent effects on subtype selectivity.

Hiroko Sano, Tomomi Noguchi, Aya Tanatani, Hiroyuki Miyachi, Yuichi Hashimoto

Index: Chem. Pharm. Bull. 52(8) , 1021-2, (2004)

Full Text: HTML

Abstract

Several N-substituted phenylphthalimide and phenylhomophthalimide derivatives with cyclooxygenase (COX)-inhibitory activity were prepared during structural development studies based on thalidomide as a lead compound. Substituent effects on the subtype selectivity were investigated.

Related Compounds

Related Articles:

Identification of the binding modes of N-phenylphthalimides inhibiting bacterial thymidylate synthase through X-ray crystallography screening.

2011-08-11

[J. Med. Chem. 54 , 5454, (2011)]

Phenylphthalimides with tumor necrosis factor alpha production-enhancing activity.

1996-01-01

[Chem. Pharm. Bull. 44(1) , 156-62, (1996)]

Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs.

1999-02-22

[Bioorg. Med. Chem. Lett. 9(4) , 559-62, (1999)]

Development of tryptase inhibitors derived from thalidomide.

2010-07-15

[Bioorg. Med. Chem. 18(14) , 5323-38, (2010)]

Glycogen phosphorylase a inhibitors with a phenethylphenylphthalimide skeleton derived from thalidomide-related alpha-glucosidase inhibitors and liver X receptor antagonists.

2009-09-01

[Biol. Pharm. Bull. 32(9) , 1618-20, (2009)]

More Articles...